A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Status:
COMPLETED
Trial end date:
2025-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC
Treatments:
Artemether, Lumefantrine Drug Combination Artesunate atovaquone, proguanil drug combination Primaquine